Cystatin C (CysC) has been the subject of extensive focus as a potential biomarker for the early diagnosis and prediction of AKI or as an alternate to the gold standard “creatinine” (Lagos-Arevalo et al., 2015). This evidence concerns the gene CST3 and acute kidney injury.